Company: MIRM
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001759425-25-000041
Chunk: 388

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 8
Chunk 388
---
 estimates may be complex and include estimates as to if and when the distributors and licensed partner’s sales in the market will occur. Estimates are reviewed and updated as additional information, including in-market sales information of our authorized distributors and licensed partners, becomes known. Actual amounts may ultimately differ from the Company’s estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. The Company is entitled to payment in connection with the supply of product under standard industry payment terms. Actual consideration amounts are determined and settled generally quarterly or annually. If the consideration received or receivable exceeds the Company’s estimates of product sales, the Company recognizes a liability. If the estimated product sales exceed the payment received or receivable, the Company records a receivable or contract asset related to the amounts not yet collected, depending on the circumstances. As of June 30, 2025, the Company did not have any contract assets.Liabilities associated with sales deductions are included in accrued expenses and other current liabilities or in other liabilities on the accompanying unaudited condensed consolidated balance sheets depending on contractual settlement timelines.The following table represents total revenues and disaggregates Product sales, net by approved medicine (in thousands): Three Months Ended June 30,Six Months Ended June 30, 2025202420252024Product sales, net:  Livmarli$88,160 $47,231 $161,384 $90,076 Bile Acid Medicines39,625 30,529 77,986 56,601 Total product sales, net127,785 77,760 239,370 146,677 License and other revenue— 115 — 420 Total revenues$127,785 $77,875 $239,370 $147,097 

9

The following table sets forth Product sales, net by geographic area based on the ship-to location (in thousands): Three Months Ended June 30,Six Months Ended June 30, 2025202420252024United States$95,532 $65,080 $182,454 $121,191 Rest of the world32,253 12,680 56,916 25,486 Total product sales, net$127,785 $77,760 $239,370 $146,677 Revenue recognized in the three and six months ended June 30, 2025 from performance obligations satisfied in previous periods